EMD Serono, USA
Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany
 
 

Global Licensing & Business Development

We are committed to investing in alliances, collaborations, in-licensing opportunities and potential acquisitions that align with our strategy to help patients with diseases across our core focus areas.

 

Global Licensing & Business Development

What we are looking for
Oncology
Our R&D groups in oncology focus on a balanced portfolio of innovative targets, as well as more established approaches. These groups are organized around five Innovation Clusters:
  • Oncogenic signaling
  • Receptor Tyrosine Kinases (RTKs) and Antibody-Drug Conjugates
  • Tumor Metabolism & Autophagy
  • Wnt & Development Pathways
  • DNA Damage & Repair
What do we seek from our partners in Oncology?
We actively search and evaluate technologies, preclinical and clinical assets that are able to support and strengthen our Innovation Clusters, and have clear differentiation potential.
Assets - Our search space includes antibodies against tumor antigens suitable for antibody-drug conjugation or pro-drug approaches for antibody therapeutics, as well as differentiated bi-specific platform technologies and antibody/protein scaffolds. Selective small molecule assets with well-defined molecular targets that show anti-tumor activity in specific contexts are also a priority, such as those with a proven synthetic lethality relationship in the area of DNA damage and repair, or those controlling tumorigenic metabolic networks in particular cancer genotypes.
Technologies - We seek methods such as those that allow the determination of drug sensitivity, detection of disease-relevant mutations in circulating DNA or tumor cells, or the identification of novel pharmacodynamic and stratification biomarkers. Such approaches might be in silico-based, or in an in vitro or in vivo setting, examples being high throughput sub-cellular analysis of drug localization/binding or innovative mouse models reflecting metabolic dependencies.
Your Contact
Catherine Pickering
Immuno-Oncology
Our focus in immuno-oncology is on actively stimulating the immune system, eliminating inhibitory mechanisms and targeting cancer stem cells. Our immuno-oncology strategy is based on three Innovation Clusters:
  • Therapeutic Cancer Vaccines
  • Tumor Immune Tolerance
  • Cancer Stem Cells
What do we seek from our partners in immuno-oncology?
We are interested in opportunities that can help us to:
  • Stimulate the immune system to enhance and redirect the body’s natural anti-tumor response;
  • Eliminate or circumvent inhibitory mechanisms that prevent cancer cells from recognition and attack by the immune system;
  • Target cancer stem cells to prevent or reduce tumor growth and inhibit the formation of metastases.
In addition to preclinical and clinical assets, we are also interested in biomarker and technology platforms for the advancement of cancer immunotherapies.
Your Contact
Catherine Pickering
Immunology
The development of therapeutics in key areas of autoimmune mediated diseases like Systemic Lupus Erythematosus (SLE), and Lupus Nephritis (LN) is our clear focus in Immunology:
  • Autoantibody-mediated diseases, stratified RA
  • Chronic inflammatory diseases with fibrosis, severe non-TH2 asthma
What do we seek from our partners in immunology?
We are interested in assets, technologies, know-how, and biomarkers. Therefore, our scope of interest may include oral, injectable or inhaled agents with mechanism of action and a testable hypothesis, or novel bi- and tri-specific biologic agents. In addition, we are also interested in novel discovery platform technologies affording us a competitive advantage, or next generation biomarkers.
Your contact
Kia Motesharei
Multiple Sclerosis
EMD Serono is committed to providing patients suffering from neurodegenerative diseases access to meaningful therapies. We employ a search and development approach to bring new therapies to market leveraging external expertise and opportunities, complemented by in-house expertise.
We seek late stage clinical assets in multiple sclerosis and related neurodegenerative diseases.
Your contact
Carrie Cook
Fertility
As a world leader in fertility treatment, we have the vision to develop and provide innovative products, devices and support services to help infertile couples at every stage of the fertility treatment cycle, from follicular development to early pregnancy.
What do we seek from our partners in Fertility?
We are interested in opportunities in adjacent treatment areas, e.g. Male Infertility, Polycystic Ovarian Syndrome, as well as assets in services, and IVF lab diagnostics.
Your contact
Ruediger Weseloh
Global Health
We have dedicated ourselves to improving access to health in under-served populations with a focus on neglected tropical diseases – especially malaria and schistosomiasis. Here we can contribute the competencies we have acquired from working at the interface of medicines, chemicals and diagnostics.
For most of these diseases, young children are the most vulnerable age group needing a suitable treatment. Our vision is to deliver integrated and affordable solutions across the continuum of care to tackle the unmet medical needs of major neglected diseases affecting children.
Your contact
Carrie Cook
Biomarkers & Technologies
We are interested in collaborating with leading scientific teams to access innovative technologies for discovery, delivery and development of small molecules and biologics across our therapeutic areas. This includes technologies to support in-house activities, such as drug characterization, formulation and development of antibody-drug-conjugates.
We are also looking for experienced partners to provide companion diagnostic development, as well as global regulatory sponsorship and worldwide commercialization of these companion diagnostics for many of our drug programs.
Your contact
Birgit Reitmaier

SERVICES